Glaukos raises 2026 guidance as iDose and Epioxa accelerate growth

Transcript intelligence

What changed

Q2 sales reached $185.6 million, up 50% year over year, and management raised full-year 2026 sales guidance to $680-$700 million. iDose TR generated $74 million in Q2, Epioxa generated $11 million, and O2N coverage reached roughly 85% of the U.S. population.

Guidance delta

Management raised full-year 2026 sales guidance to $680-$700 million from the prior quarter's $620-$635 million range.

Key takeaways

• iDose TR generated $74 million in Q2 and management expects it to support roughly 50% annual growth in U.S. glaucoma sales.
• Epioxa generated $11 million in Q2, with physician interest and payer coverage expanding.
• International glaucoma sales grew 17% year over year, supported by iStent infinite certification and market launches.
• O2N coverage reached roughly 85% of the U.S. population, with a goal of 95%.
• Management is advancing multiple pipeline programs while targeting operating leverage and cash-flow breakeven.

Management priorities

• Expand iDose TR adoption and advance the iDose TREX and TRIO programs.
• Scale Epioxa commercial access through payer coverage, co-pay assistance, and specialty pharmacy programs.
• Expand O2N coverage toward 95% of the U.S. population.
• Advance pipeline programs across glaucoma, corneal health, retinal disease, and related platforms.